1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Nephrocalcinosis: new trials by email Literature Review of Nephrocalcinosis trials Research Report on Nephrocalcinosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 Encaleret, Standard of Care - Autosomal Dominant Hypocalcemia (ADH) | Phase 3 | Active not recruiting | Calcilytix Therapeutics, Inc., a BridgeBio company | 67 | 2023-01-06 | 2026-07-29 |
Calcium Metabolism Disorders (1) · Hypercalciuria (1) · Hypercalciuric Hypocalcemia, Familial (1) · Hypocalcemia (1) · Hypoparathyroidism (1) · Metabolic Diseases (1) · Muscular Diseases (1) · Musculoskeletal Abnormalities (1) · Musculoskeletal Diseases (1) · Nephrolithiasis (1)
Calcinosis (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Nervous System Diseases (1) · Neuromuscular Diseases (1) · Nutritional and Metabolic Diseases (1) · Parathyroid Diseases (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Urogenital Diseases (1)
Standard of Care (1)
Calcilytix Therapeutics, Inc., a BridgeBio company (1)
Australia (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Italy (1) · Japan (1) · Netherlands (1) · United Kingdom (1) · United States (1)